Related Experiment Videos
Brain astrocytomas: biopsy, then irradiation
L D Lunsford1, S Somaza, D Kondziolka
1Department of Neurological Surgery, Radiology and Radiation Oncology, University of Pittsburgh Medical Center, Pennsylvania, USA.
Clinical Neurosurgery
|January 1, 1995
Summary
Early diagnosis and treatment are crucial for low-grade glial neoplasms, as observation is not warranted due to poor survival rates. Aggressive treatment, including stereotactic biopsy, may improve outcomes for astrocytoma patients.
Area of Science:
- Neuro-oncology
- Neurosurgery
- Oncology
Background:
- Low-grade glial neoplasms present a diagnostic and therapeutic challenge.
- Current management strategies, including observation and cytoreductive surgery, have limitations.
- The median survival for untreated tumors is poor, necessitating a re-evaluation of treatment paradigms.
Purpose of the Study:
- To advocate for early diagnosis and treatment of suspected low-grade glial neoplasms.
- To emphasize the limitations of observation and the need for evidence-based treatment strategies.
- To highlight the potential benefits of early stereotactic biopsy and tailored aggressive treatments.
Main Methods:
- Retrospective analysis of patients with suspected low-grade glial neoplasms.
- Application of a treatment philosophy prioritizing early diagnosis and intervention.
- Comparison of outcomes between different treatment approaches, including observation, surgery, and radiation therapy.
Main Results:
- Patients treated with early diagnosis and intervention achieved a median survival exceeding 10 years.
- Most patients maintained a high Karnofsky Performance Status (KPS) rating.
- Early stereotactic biopsy identified aggressive tumors, enabling timely and appropriate treatment.
Conclusions:
- Observation is not a suitable strategy for suspected glial neoplasms due to poor prognosis.
- Early diagnosis and tailored aggressive treatment, potentially including stereotactic biopsy, can significantly improve survival and quality of life.
- Further research is needed to optimize therapeutic options and develop novel strategies for glial tumor management.